tiprankstipranks
Microbot Medical Advances in Clinical Trials and FDA Process
Company Announcements

Microbot Medical Advances in Clinical Trials and FDA Process

Don't Miss Our Christmas Offers:

Microbot Medical (MBOT) has provided an announcement.

Microbot Medical Inc. has reached a significant milestone by completing the enrollment of clinical trial sites, adding the prestigious Memorial Sloan Kettering Cancer Center to its roster for the pivotal trial of the LIBERTY® Endovascular Robotic Surgical System. This achievement is a step towards the system’s anticipated FDA submission and eventual market launch. However, investors are cautioned that these forward-looking statements are not guarantees of future performance and are subject to various factors that could impact actual results.

See more data about MBOT stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMicrobot Medical Stockholders Approve Key Proposals in 2024
TipRanks Auto-Generated NewsdeskMicrobot Medical Advances with LIBERTY® FDA Submission
TheFlyMicrobot Medical announces FDA submission for commercialization of LIBERTY
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App